Second Sight Announces Expansion of Medicare Coverage for Argus II
Retinal Prosthesis System to 11 Additional States and the District of
Columbia

-- Argus II Can Now Be Covered in Seven of 12 Medicare Administrative
Contractor Jurisdictions, representing a total of 28 states, two
territories, and the District of Columbia --

July 03, 2017 08:00 AM Eastern Daylight Time

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or
"the Company"), a developer, manufacturer and marketer of implantable
visual prosthetics to provide some useful vision to blind patients,
today announced the Argus II® Retinal Prosthesis System (“Argus
II”) can now be covered by Medicare in seven of the 12 Medicare
Administrative Contractor (“MAC”) jurisdictions nationwide, representing
a total of 28states, two territories, and the District of
Columbia.

The MAC for jurisdictions JH and JL, Novitas Solutions, Inc. (“Novitas”)
published a local coverage determination removing the Category III
Current Procedural Terminology Code that describes the Argus II
placement procedure (0100T) from the listing of codes that are
considered not reasonable and necessary. This decision authorizes
coverage of Argus II, when medically necessary, to Medicare
beneficiaries in Arkansas, Colorado, Delaware, Louisiana, Maryland,
Mississippi, New Jersey, New Mexico, Oklahoma, Pennsylvania, Texas, and
the District of Columbia.

Will McGuire, President and CEO of Second Sight, said, “We are pleased
that Novitas has made this important decision to facilitate coverage of
the Argus II, which we believe will enable us to offer greater access to
patients with Retinitis Pigmentosa and continue to fulfill our mission
of providing useful vision to the blind.”

Second Sight continues to work with other MACs and payers to secure
affirmative coverage policies for the Argus II and to ensure that
Medicare beneficiaries nationwide have access to this revolutionary
technology.

About the Argus II Retinal Prosthesis System

Second Sight's Argus II System provides electrical stimulation that
bypasses the defunct retinal cells and stimulates remaining viable cells
inducing visual perception in individuals with severe to profound
Retinitis Pigmentosa. The Argus II works by converting images captured
by a miniature video camera mounted on the patient's glasses into a
series of small electrical pulses, which are transmitted wirelessly to
an array of electrodes implanted on the surface of the retina. These
pulses stimulate the retina's remaining cells, intending to result in
the perception of patterns of light in the brain. The patient must learn
to interpret these visual patterns, having the potential to regain some
visual function. The Argus II was the first artificial retina to receive
widespread approval, and is offered at approved centers in Canada,
France, Germany, Italy, Saudi Arabia, Spain, Taiwan, Turkey, United
Kingdom, and the U.S.

About Second Sight

Second Sight's mission is to develop, manufacture and market innovative
implantable visual prosthetics to enable blind individuals to achieve
greater independence. Second Sight has developed and manufactures the
Argus® II Retinal Prosthesis System. Second Sight is currently
conducting a trial to test the safety and utility of the Argus II in
individuals with Dry Age-Related Macular Degeneration. Second Sight is
also developing the Orion™ I Visual Cortical Prosthesis that is intended
to restore some vision to individuals who are blind due to many causes
other than preventable or treatable conditions. U.S. Headquarters are in
Sylmar, CA, and European Headquarters are in Lausanne, Switzerland. For
more information, visit www.secondsight.com.

Safe Harbor

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange and Exchange Act of 1934, as
amended, which are intended to be covered by the "safe harbor" created
by those sections. All statements in this release that are not based on
historical fact are "forward looking statements." These statements may
be identified by words such as "estimates," "anticipates," "projects,"
"plans," or "planned," "seeks," "may," "will," "expects," "intends,"
"believes," "should" and similar expressions or the negative versions
thereof and which also may be identified by their context. All
statements that address strategies, estimated size of potential markets,
anticipated expansion of MAC coverage, operating performance or events
or developments that Second Sight expects or anticipates will occur in
the future, or that are not otherwise historical facts, are
forward-looking statements. While management has based any forward
looking statements included in this release on its current expectations,
the information on which such expectations were based may change.
Forward-looking statements involve inherent risks and uncertainties
which could cause actual results to differ materially from those in the
forward-looking statements, as a result of various factors including
those risks and uncertainties described in the Risk Factors and in
Management's Discussion and Analysis of Financial Condition and Results
of Operations sections of our Annual Report on Form 10-K as filed
on March 16, 2017, and our other reports filed from time to time with
the Securities and Exchange Commission. We urge you to consider those
risks and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made. Except
as otherwise required by the federal securities laws, we disclaim any
obligation or undertaking to publicly release any updates or revisions
to any forward-looking statement contained herein (or elsewhere) to
reflect any change in our expectations with regard thereto or any change
in events, conditions or circumstances on which any such statement is
based.